<DOC>
	<DOC>NCT00747786</DOC>
	<brief_summary>The purpose of this study, is to assess the safety and local tolerability of the long-term use of Somatuline Autogel when administered by patients or their partners ("Home Injection Group") and the safety and local tolerability in patients receiving their injection from a healthcare professional (HCP) ("Reference Group").</brief_summary>
	<brief_title>Non Interventional Post Marketing Programme in Neuroendocrine Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<criteria>The patient must give written (personally signed and dated) informed consent for their data to be included in the database for this Post Marketing Surveillance programme and any subsequent analysis. The patient must have been receiving treatment with Somatuline Autogel at a stable dose for at least 4 months. The patient must have a diagnosis of neuroendocrine tumours The patient must be at least 18 years of age For patients receiving or intending to receive Somatuline Autogel by home injection: The patient must be able to store Somatuline Autogel safely in a refrigerator in their own home and either collect it from their GP/Pharmacy on a monthly basis, or receive the medication by a home delivery service. The patient is pregnant or breastfeeding, unless continued treatment with Somatuline Autogel is clearly needed (as determined by the treating clinician).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>